Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06413706 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
A Phase 2 study of Glioma, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06413706: Active Phase 2 study of Glioma, sponsored by Eli Lilly and Company.
NCT06413706 is a Phase 2 study of Glioma that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 45 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06413706, a Phase 2 study of Glioma, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Primary Outcome
Event free survival as determined by blinded independent review committee.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Abemaciclib
Study Locations (20)
Other
- Queensland Government- Lady Cilento Children's Hospital - Brisbane
- Perth Children's Hospital - Nedlands
- The Children's Hospital at Westmead - Westmead
- Universitair Ziekenhuis Gent (Uz Gent) - Ghent
- Universitair Ziekenhuis Leuven - Leuven
- Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Copenhagen University Hospital-Rigshospitalet University Hospital - Copenhagen
- Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin Hopital des Enfants - Bordeaux
- Centre de Lutte Contre le Cancer (CLCC) - Centre Oscar Lambret - Lille
- Centre Leon Berard - Lyon
- Hopital La Timone - Marseille
California
- Children's Hospital of Orange County - Orange - Orange
- Lucile Packard Children's Hospital (LPCH) - Stanford University - Palo Alto
Texas
- UT Southwestern Medical Center Dallas/Childrens Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Indiana
- Riley Hospital for Children at Indiana University Health - Indianapolis
Maryland
- The Johns Hopkins Hospital (JHH) - Johns Hopkins Childrens Center - Baltimore
Michigan
- University of Michigan Health System (UMHS) - C.S. Mott Children's Hospital - Hematology Oncology Clinic - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What the registry record for NCT06413706 still lists
NCT06413706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT06413706 names 20 study sites across 8 states, led by Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06413706 about?
NCT06413706 is a clinical study titled "A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy". The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
What is the current status of trial NCT06413706?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-10-25. Estimated completion is 2028-02.
What conditions does trial NCT06413706 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT06413706?
The interventions under investigation include: Temozolomide (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT06413706?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06413706 being conducted?
This trial has 20 study locations across California, Indiana, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06413706's enrollment target sits among peer trials
45 41st of 87 higher than 47 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RECRUITING · Phase 2
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Methimazole in Patients With Progressive Glioblastoma
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI